National Library of Medicine; Notice of Closed Meetings, 71078-71079 [2020-24669]
Download as PDF
<![CDATA[
71078
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
C. Annual Burden
A. Purpose
Respondents: 28,399.
Total Annual Responses: 148,094.
Total Burden Hours: 9,160,160.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the GSA
Regulatory Secretariat Division by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov.
Please cite OMB Control No. 9000–
0013, Certified Cost or Pricing Data and
Data Other Than Certified Cost or
Pricing Data.
This information requirement consists
of reports that do not impose collection
burdens upon the public. These
collections require information which is
already available to the public at large,
or that is routinely exchanged by firms
during the normal course of business. A
general control number for these
collections decreases the amount of
paperwork generated by the approval
process.
Under clause 552.238–73,
‘‘Identification of Electronic Office
Equipment Providing Accessibility for
the Handicapped,’’ (previous clause
number 552.238–70) the offeror is
encouraged to identify office equipment,
including any special peripheral that
will facilitate electronic office
equipment accessibility for
handicapped individuals in its
commercial catalogs and pricelists
accepted by the Government.
William F. Clark,
Director, Office of Government-wide
Acquisition Policy, Office of Acquisition
Policy, Office of Government-wide Policy.
[FR Doc. 2020–24614 Filed 11–5–20; 8:45 am]
BILLING CODE 6820–EP–P
GENERAL SERVICES
ADMINISTRATION
B. Annual Reporting Burden
[OMB Control No. 3090–0250; Docket No.
2020–0001; Sequence No. 7]
None.
C. Public Comments
Information Collection; General
Services Administration Acquisition
Regulation; Zero Burden Information
Collection Reports
Office of the Chief Acquisition
Officer, General Services
Administration (GSA).
ACTION: Notice of request for public
comments regarding an extension to an
existing OMB information collection.
AGENCY:
SUMMARY: Under the provisions of the
Paperwork Reduction Act, the
Regulatory Secretariat Division (MVCB)
will be submitting to the Office of
Management and Budget (OMB) a
request to review and approve an
extension of a previously approved
information collection requirement
regarding Zero Burden Information
Collection Reports.
DATES: Submit comments on or before:
December 7, 2020.
ADDRESSES: Written comments and
recommendations for this information
collection should be sent within 30 days
of publication of this notice to
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function.
FOR FURTHER INFORMATION CONTACT: Mr.
Thomas O’Linn, Procurement Analyst,
General Services Acquisition Policy, at
202–445–0390 or via email at
Thomas.olinn@gsa.gov
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:29 Nov 05, 2020
Jkt 253001
A 60-day notice published in the
Federal Register at 85 FR 53003 on
August 27, 2020. No comments were
received.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW, Washington, DC
20405, telephone 202–501–4755. Please
cite OMB Control No. 3090–0250, Zero
Burden Information Collection Reports,
in all correspondence.
Jeffrey A. Koses,
Senior Procurement Executive, Office of
Acquisition Policy, Office of Governmentwide Policy.
[FR Doc. 2020–24725 Filed 11–5–20; 8:45 am]
BILLING CODE 6820–61–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Clinical and Data
Coordinating Center; Applications for NCCIH
Multi-Site Clinical Trials of Mind and Body
Interventions.
Date: November 30, 2020.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Complementary
and Integrative, DEM II, 6707 Democracy
Blvd., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Pamela Jeter, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, Division of Extramural Activities,
NCCIH, NIH, 6707 Democracy Boulevard,
Suite 401, Bethesda, MD 20892–547, 301–
435–2591, pamela.jeter@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24667 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; Conflicted
SEP.
Date: December 10, 2020.
Time: 10:00 a.m. to 1:00 p.m.
E:\FR\FM\06NON1.SGM
06NON1
71079
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
Agenda: To review and evaluate grant
applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D.,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda,
MD 20892–7968, 301–827–7077, tsapl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24669 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Clinical trials
for COVID 19 management in older
individuals.
Date: December 11, 2020.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maurizio Grimaldi, MD,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin
Avenue, Gateway Building, Suite 2W200,
Bethesda, MD 20892, (301) 496–9374,
grimaldim2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: November 2, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24615 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
SUMMARY: The National Heart, Lung and
Blood Institute (NHLBI) and the
National Human Genome Research
Institute (NHGRI), both of the National
Institutes of Health, Department of
Health and Human Services, are
contemplating the grant of an exclusive
patent license to Inversago Pharma Inc.,
located in Montreal, Quebec, Canada, to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
Only written comments and/or
applications for a license which are
received by the National Human
Genome Research Institute’s Technology
Transfer Office on or before November
23, 2020 will be considered.
DATES:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Anna Solowiej, Ph.D., J.D.,
Senior Licensing and Patenting
Manager, NHGRI Technology Transfer
Office; Telephone (301) 435–7791;
Email: anna.solowiej@nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Inversago Pharma Inc.:
Prospective Grant of Exclusive Patent
License: Treatment of HermanskyPudlak Syndrome and Idiopathic
Pulmonary Fibrosis
National Institutes of Health,
HHS.
NIH ref No.
Patent No. or
application No.
Issue date
Filing date
E–282–2012–0–US–01 ..........
E–282–2012–0–PCT–02 ........
E–282–2012–0–US–03 ..........
E–282–2012–0–CA–04 ..........
E–282–2012–0–EP–05 ..........
E–282–2012–0–CH–12 ..........
E–282–2012–0–DE–13 ..........
E–282–2012–0–FR–14 ..........
E–282–2012–0–GB–15 ..........
E–282–2012–0–IE–16 ...........
E–282–2012–0–IN–06 ...........
E–282–2012–0–JP–07 ...........
E–282–2012–0–CN–08 ..........
E–282–2012–0–US–09 ..........
E–282–2012–0–US–10 ..........
E–282–2012–0–US–11 ..........
E–282–2012–1–US–01 ..........
E–282–2012–1–PCT–02 ........
E–282–2012–1–EP–05 ..........
E–282–2012–1–US–08 ..........
E–282–2012–1–US–09 ..........
E–282–2012–2–US–01 ..........
E–282–2012–2–PCT–02 ........
E–282–2012–2–CN–03 ..........
E–282–2012–2–EP–04 ..........
E–140–2014–0–US–01 ..........
E–140–2014–0–PCT–02 ........
E–140–2014–0–AU–03 ..........
E–140–2014–0–CA–04 ..........
E–140–2014–0–CN–05 ..........
61/725,949 ....................
PCT/US2013/069686 ...
9,765,031 ......................
2889697 ........................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
3733/DELNP/2015 ........
6272626 ........................
ZL201380069389.9 ......
10,683,270 ....................
15/674,333 ....................
16/870,093 ....................
62/171,179 ....................
PCT/US2016/035291 ...
16728547.7 ...................
15/579,123 ....................
16/438,850 ....................
15/061,829 ....................
PCT/US2017/020250 ...
2017800118698 ............
17711443.6 ...................
61/991,333 ....................
PCT/US2015/029946 ...
2015255765 ..................
2948349 ........................
201580028788.X ..........
...............................................
...............................................
September 19, 2017 ............
...............................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
...............................................
January 12, 2018 .................
August 20, 2019 ...................
June 16, 2020 ......................
TBD (application allowed) ....
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
February 7, 2020 ..................
November 13, 2012 ......
November 12, 2013 ......
November 12, 2013 ......
April 27, 2015 ...............
June 01, 2015 ..............
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
May 1, 2015 .................
May 11, 2015 ...............
July 3, 2015 ..................
August 10, 2017 ...........
August 10, 2017 ...........
May 8, 2020 .................
June 4, 2015 ................
June 1, 2016 ................
June 1, 2016 ................
December 1, 2017 ........
June 12, 2019 ..............
March 4, 2016 ..............
March 1, 2017 ..............
March 1, 2017 ..............
March 1, 2017 ..............
May 9, 2014 .................
May 8, 2015 .................
November 7, 2016 ........
May 8, 2015 .................
May 8, 2015 .................
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
Notice.
SUPPLEMENTARY INFORMATION:
National Institutes of Health
AGENCY:
ACTION:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Title
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
E:\FR\FM\06NON1.SGM
06NON1
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
]]>Agencies
[Federal Register Volume 85, Number 216 (Friday, November 6, 2020)]
[Notices]
[Pages 71078-71079]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24669]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Library of Medicine Special Emphasis
Panel; Conflicted SEP.
Date: December 10, 2020.
Time: 10:00 a.m. to 1:00 p.m.
[[Page 71079]]
Agenda: To review and evaluate grant applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D., Scientific Review
Officer, Extramural Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-
7077, [email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.879,
Medical Library Assistance, National Institutes of Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24669 Filed 11-5-20; 8:45 am]
BILLING CODE 4140-01-P
